Vincristine (NSC-67574) sulfate

Name: Vincristine (NSC-67574) sulfate
Brand: Selleck Chemicals
SKU: S1241
Rating: 5 (83 reviews)

For research use only.

Catalog No.S1241 Synonyms: Leurocristine, Oncovin, 22-Oxovincaleukoblastine

83 publications

Vincristine (NSC-67574) sulfate Chemical Structure

CAS No. 2068-78-2

Vincristine sulfate (NSC-67574, Leurocristine, Oncovin, 22-Oxovincaleukoblastine) is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay. Vincristine sulfate induces apoptosis.

Selleck's Vincristine (NSC-67574) sulfate has been cited by 83 publications

Cancer Discov, 2019, 9(2):230-247

PubMed: 30373918 ( click the link to review the publication )

Cancer Cell, 2017, 31(6):833-843

PubMed: 28552327 ( click the link to review the publication )

Theranostics, 2021, 11(9):4281-4297

PubMed: 33754061 ( click the link to review the publication )

Cell Rep, 2021, 35(13):109302

PubMed: 34192534 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E361

PubMed: 33478100 ( click the link to review the publication )

Mol Cancer Ther, 2021, 10.1158/1535-7163.MCT-20-0864

PubMed: 33850006 ( click the link to review the publication )

J Neurochem, 2021, 156(5):642-657

PubMed: 32654140 ( click the link to review the publication )

Invest New Drugs, 2021, 10.1007/s10637-020-01003-3

PubMed: 33475937 ( click the link to review the publication )

Chem Biol Interact, 2021, 340:109448

PubMed: 33775687 ( click the link to review the publication )

Toxicol Lett, 2021, 340:67-76

PubMed: 33429010 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2021, gmab101

PubMed: 34363072 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Cold Spring Harb Mol Case Stud, 2021, mcs.a006049

PubMed: 33722797 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-20-1315

PubMed: 32826328 ( click the link to review the publication )

Oncogene, 2020, 39(17):3555-3570

PubMed: 32123312 ( click the link to review the publication )

Environ Sci Technol, 2020, 54(23):15267-15276

PubMed: 33201683 ( click the link to review the publication )

Cancer Lett, 2020, 469:111-123

PubMed: 31639426 ( click the link to review the publication )

J Pathol, 2020, 10.1002/path.5591

PubMed: 33206391 ( click the link to review the publication )

BMC Biol, 2020, 22;18(1):42

PubMed: 32321486 ( click the link to review the publication )

Arch Toxicol, 2020, 10.1007/s00204-020-02933-w

PubMed: 33057863 ( click the link to review the publication )

Mol Cancer Ther, 2020, 25;molcanther.1021.2019

PubMed: 32451331 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(23):24424-24440

PubMed: 33291076 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(8):2649-2676

PubMed: 32905466 ( click the link to review the publication )

PLoS Negl Trop Dis, 2020, 17;14(4):e0008224

PubMed: 32302296 ( click the link to review the publication )
Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Toxicology, 2020, 429:152329

PubMed: 31733235 ( click the link to review the publication )

Vet Comp Oncol, 2020, 10.1111/vco.12656

PubMed: 33025640 ( click the link to review the publication )

Biol Open, 2020, bio.050211

PubMed: 33372065 ( click the link to review the publication )

Cell Biol Int, 2020, 44(2):610-620

PubMed: 31743535 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Mol Med Rep, 2020, 22(4):2791-2800

PubMed: 32945456 ( click the link to review the publication )

Neuroreport, 2020, 31(3):197-204

PubMed: 31834144 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33202

PubMed: 32638373 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13124

PubMed: 32753665 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):95

PubMed: 32677976 ( click the link to review the publication )

Int J Med Sci, 2020, 17(11):1652-1664

PubMed: 32669967 ( click the link to review the publication )

Cancer Res, 2019, 79(20):5382-5393

PubMed: 31405846 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Rep, 2019, 26(6):1544-1556

PubMed: 30726737 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 31742555 ( click the link to review the publication )

J Lipid Res, 2019, 60(6):1078-1086

PubMed: 30962310 ( click the link to review the publication )

Biochem Pharmacol, 2019, 170:113642

PubMed: 31541631 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(24)E6175

PubMed: 31817853 ( click the link to review the publication )

J Cell Biochem, 2019, 120(10):17791-17810

PubMed: 31264739 ( click the link to review the publication )

Oncotarget, 2019, 10(60):6403-6417

PubMed: 31741706 ( click the link to review the publication )

J Exp Med, 2018, 215(8):2137-2155

PubMed: 30045945 ( click the link to review the publication )
Cell Death Dis, 2018, 9(11):1070

PubMed: 30341283 ( click the link to review the publication )

Cell Cycle, 2018, 17(5):652-668

PubMed: 28749250 ( click the link to review the publication )

SLAS Discov, 2018, 23(7):687-696

PubMed: 29865911 ( click the link to review the publication )

J Exp Med, 2018, 215(12):3094-3114

PubMed: 30404791 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36413-36429

PubMed: 30559927 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1965

PubMed: 30530705 ( click the link to review the publication )

Leukemia, 2018, 32(3):616-625

PubMed: 28904384 ( click the link to review the publication )

Chemosphere, 2018, 210:467-475

PubMed: 30025364 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9273-9284

PubMed: 29507689 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Clin Cancer Res, 2017, 15;23(10):2506-2515

PubMed: 27780854 ( click the link to review the publication )

J Cell Biol, 2017, 216(11):3655-3675

PubMed: 28877995 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(8):1555-1565

PubMed: 28522589 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Int J Oncol, 2017, 51(1):257-268

PubMed: 28534954 ( click the link to review the publication )

Oncotarget, 2017, 8(12):18626-18639

PubMed: 28148893 ( click the link to review the publication )

Oncotarget, 2017, 8(24):39064-39076

PubMed: 28388564 ( click the link to review the publication )

Drugs R D, 2017, 17(2):287-296

PubMed: 28299646 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29245981 ( click the link to review the publication )

Cell Death & Disease, 2017, 10.1038/cddis.2017.454

PubMed: ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1335-1351

PubMed: 28496304 ( click the link to review the publication )
BMC Pharmacol Toxicol, 2017, 18(1):63

PubMed: 28877739 ( click the link to review the publication )

ACS Cent Sci, 2016, 2(8):545-59

PubMed: 27610416 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(32):9015-20

PubMed: 27450084 ( click the link to review the publication )

Lipids Health Dis, 2016, 15:152

PubMed: 27613245 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(10):909-919

PubMed: 27358112 ( click the link to review the publication )

Int J Anal Chem, 2015, 2015:743915

PubMed: 27034675 ( click the link to review the publication )

Cell Rep, 2015, 13(11):2353-2361

PubMed: 26686626 ( click the link to review the publication )

J Pharmacol Exp Ther, 2014, 350(3):646-56

PubMed: 24993360 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):10736-49

PubMed: 23109819 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description

Targets

Microtubules ^[1]
(Cell-free assay)

32 μM

In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with K_i of 85 nM. ^[1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. ^[2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. ^[4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HepG2.2.15	NYnZ[ItQS2WubDDWbYFjcWyrdImgRZN{[Xl?	MX[wMVAvPSEQvF2=	NW\WdYJLOjRiaB?=		NWWxU2pn\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm=	M1S4R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nk[zO\|Y6Lz5{NU[2N\|c3QTxxYU6=
HepG2-HBV1.1	MWjBdI9xfG:\|aYOgRZN{[Xl?	NILIe5ExNTBwNTFOwG0>	MonxNlQhcA>?		NETU[XFqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	M4S4OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nk[zO\|Y6Lz5{NU[2N\|c3QTxxYU6=
HepG2.2.15	MoO0SpVv[3Srb36gRZN{[Xl?	M17SRlAvOSEQvF2=	M2fjdlI1KGh?		NV\LXHBbeHKxbX;0[ZMhcGWyYYTpeIl{KEJidnnyeZMheHKxdHXpckBmgHC{ZYPzbY9v	Ml[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NkO3OlkoRjJ3Nk[zO\|Y6RC:jPh?=
HepG2-HBV1.1	NUHzNoIyTnWwY4Tpc44hSXO\|YYm=	MYKwMlEh\|ryP	MWGyOEBp		MnLHdJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO\|aX;u	M3S0e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nk[zO\|Y6Lz5{NU[2N\|c3QTxxYU6=
HepG2-HBV1.1	NV2zfphDTnWwY4Tpc44hSXO\|YYm=	MYCwMlEh\|ryP	M2fxeVQ5KGh?		MXvwdo9ud3SnczDj[YxtKGW6Y4LleIlwdiCxZjDo[ZBifGm2aYOgRkB3cXK3czDueYNt\W:lYYDzbYR{KGmwc4TlZYQhd2ZiaHXwZZRqfGm\|IFKgeolzfXNiRHHu[UBx[XK2aXPs[ZM>	NH:xN4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[2N\|c3QSd-MkW2OlM4Pjl:L3G+
HepG2-HBV1.1	Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX:wMlEh\|ryP	NGK5VnoyNTViZB?=		MYHpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjD0bY1mKGSncHXu[IVvfGy7	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ4M{e2PUc,OjV4NkO3Olk9N2F-
HepG2-HBV1.1	MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTETlcxNjFizszN	MYOxMVUh\A>?		MXzpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjD0bY1mKGSncHXu[IVvfGy7	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ4M{e2PUc,OjV4NkO3Olk9N2F-
HepG2-HBV1.1	MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\kNE4yKM7:TR?=	M3rSU\|EzNTd{IHi=		M17xRolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhWy2yaHHz[S=>	NVjONXNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OlM4PjlpPkK1OlY{PzZ7PD;hQi=>
HepG2-HBV1.1	NFvKZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrIN3IxNjFizszN	NV;UXpJbOTJvN{KgbC=>		NVXNfY9WcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCVLYDoZZNm	NVzPSI5lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OlM4PjlpPkK1OlY{PzZ7PD;hQi=>
Raji	NV32ToQ2TnWwY4Tpc44hSXO\|YYm=	NYPwSmZJOC53wrFOwG0>	NIHx[HY4OiCq		NFjpcpdi[m:uaYPo[ZMh[XW2b4DoZYd6yqB?	NX75dI5iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OFY{PzdpPkK1OFQ3Ozd5PD;hQi=>
SK-MEL-28	M2fKeGZ2dmO2aX;uJGF{e2G7	Mn7BN\|Ahdk1?	NGXtcGM3KGh?		MX3pcoR2[2W\|IFey5qCUVSClZXzsMYN6[2ynIHHydoV{fA>?	NH;jbIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOxN\|AyOCd-MkWzNVMxOTB:L3G+
H157	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfoXXFxUUN3ME2xMlA{KMLzIECuNFQhdWm3Ml2=	M4\mZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkW3PVEyLz5{NUK1O\|kyOTxxYU6=
Jurkat	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\INU0{KG6P	MnO5OFjDqGh?	Mo\XSG1UVw>?	MoHo[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:\|ZTDk[ZBmdmSnboTsfS=>	MnLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNU[xOFYoRjJ3MUW2NVQ3RC:jPh?=
CEM	NF[1UHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLFNU0{KG6P	MVy0POKhcA>?	MnTzSG1UVw>?	M2T1dIRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3NkG0Okc,OjVzNU[xOFY9N2F-
P12	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PDdVEuOyCwTR?=	NX70bXZrPDkEoHi=	MWDEUXNQ	MlXQ[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:\|ZTDk[ZBmdmSnboTsfS=>	NEPGZWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1OlE1Pid-MkWxOVYyPDZ:L3G+
KB	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjuTWM2OD1yLkCwOFkhyrFiMD6wNFAyKM7:TR?=	MnPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUi1NlYoRjJ3MEW4OVI3RC:jPh?=
KBv200 (ABCB1)	NGT6SVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;LTWM2OD1yLkO0OlIhyrFiMD6wNFY3KM7:TR?=	M1u1eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEW4OVI3Lz5{NUC1PFUzPjxxYU6=
SUDHL6	NGO0bY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnuxNgKBkc7:TR?=	MoW2OFgwPzJiaB?=		NXzvcFhkcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>?	NUHIUJFbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlE3ODRpPkK0PVYyPjB2PD;hQi=>
SUDHL6	M3jjbmZ2dmO2aX;uJGF{e2G7	MUex5qCK\|ryP	MkLOO\|IhcA>?		NWrlR3BbcW6mdXPld{B{cWewaX\pZ4FvfCCjcH;weI91cWNibX;ydIhwdG:peTDjbIFv\2W\|IHPveJJme3SnZDD3bZRpKEKFTEGxRUB{cVKQQR?=	M1P2VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OU[xOlA1Lz5{NEm2NVYxPDxxYU6=
HCT-116	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnvNXBLT0l3ME21JI5O	Mn3MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7Mke4OVcoRjJ2OUK3PFU4RC:jPh?=
SKNBe2C	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILXZVBKSzVyPUOyMljDuTRwMDDuUS=>	M1jKXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUKxPVIxLz5{NEmyNVkzODxxYU6=
IGNR91	M4ji[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\5UIZKSzVyPUK0MlPDuTFwNzDuUS=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl{MUmyNEc,OjR7MkG5NlA9N2F-
SKNAS	MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTFwNdMxNE4zKG6P	MlrLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MkG5NlAoRjJ2OUKxPVIxRC:jPh?=
LAN1	NUfzWoxnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTJwM9MxNE4zKG6P	NEW4WoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmyNVkzOCd-MkS5NlE6OjB:L3G+
SHSY5Y	NWSxWINWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRThwMtMxNE43KG6P	NYnFcmQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NlE6OjBpPkK0PVIyQTJyPD;hQi=>
A549-WT	MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTF7LkSzO{DDuSByLkW5OEAhdk1?	M3Tlc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEW4PFI4Lz5{NEi1PFgzPzxxYU6=
A549-R	NHjwXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTF{LkG3PEDDuSByLkOzN{Ahdk1?	NWrIT2F7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OVg5OjdpPkK0PFU5QDJ5PD;hQi=>
MCF-7-WT	MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYS5e2xTUUN3ME2xO{44PTJiwsGgNE4zOThiIH7N	NW\oNnNrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OVg5OjdpPkK0PFU5QDJ5PD;hQi=>
MCF-7-R	NXrhTIpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XCUmlEPTB;NT61N\|khyrFiMD6xOFQhKG6P	M1;lcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEW4PFI4Lz5{NEi1PFgzPzxxYU6=
A549-R	NVPjfYdiS3m2b4TvfIlkcXS7IFHzd4F6				NWfnNWtvUUN3ME2xNk4yPzhiwsGgNE4{OzNibl2=	MkHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NUi4NlcoRjJ2OEW4PFI4RC:jPh?=
MCF-7-R	NGTGZXZEgXSxdH;4bYNqfHliQYPzZZk>				M2jZdmlEPTB;NT61N\|khyrFiMD6xOFQhdk1?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh3OEiyO{c,OjR6NUi4Nlc9N2F-
SW620	M2n3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DtZmlEPTB;Nz64NEDDuSByLkC4JI5O	NEn6XVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyOlc{QSd-MkS3NlY4Ozl:L3G+
SW620/AD300	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7t[Fd4UUN3ME25NFkvPjBiwsGgPE46OSCwTR?=	M2rh[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K2O\|M6Lz5{NEeyOlc{QTxxYU6=
HEK293/pcDNA3.1	NVjKRVN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPhbpQ6UUN3ME2xMlQ2KMLzIECuNlAhdk1?	NUW5V3NWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlY4OzlpPkK0O\|I3PzN7PD;hQi=>
HEK293/ABCC1	NIj0RVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTF7LkK5JOKyKDJwMEigcm0>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{NkezPUc,OjR5Mk[3N\|k9N2F-
TCC	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmfaNlQhcA>?		NFXsU3VKSzVyPUewJI5O	NH;mNI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEexOlk1PCd-MkS3NVY6PDR:L3G+
TCC	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmPYOFghcA>?		NVfhSlRHUUN3ME21NEBvVQ>?	NFPQWYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEexOlk1PCd-MkS3NVY6PDR:L3G+
HepG2/ADM	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHMTWM2OD1{Lke4OlPDuTBwMkO3NUDPxE1?	MoLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5MES1OVYoRjJ2N{C0OVU3RC:jPh?=
HepG2	NIP1TJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfSd4lKSzVyPUCuNFEyPcLzMD6wNFE4KM7:TR?=	NIfHeGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEewOFU2Pid-MkS3NFQ2PTZ:L3G+
MCF-7/ADR	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TPVmlEPTB;ND60PFI3yrFyLkKwO\|Ah\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDdyNEW1Okc,OjR5MES1OVY9N2F-
MCF-7	M161bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTBwMEG1PeKyOC5yME[yJO69VQ>?	M1vLOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{C0OVU3Lz5{NEewOFU2PjxxYU6=
A-172	MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUCwMlHDqM7:TR?=	MX6yOE84OiCq		NHe5N3NqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6	NWDHdFk4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1N\|AzOzVpPkK0OVMxOjN3PD;hQi=>
U-251MG	M{Hjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULjbmhJOC5zwrFOwG0>	MX2yOE84OiCq		NFHDVmtqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6	NXnTUo9uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1N\|AzOzVpPkK0OVMxOjN3PD;hQi=>
DLD-1	MYTGeY5kfGmxbjDBd5NigQ>?	NXjFbIRiOTByIH7N	NYnpe\|d2PDhiaB?=		NHPFO5hxem:vb4Tld{BTXU6[MzDk[Y1mfGi7bHH0bY9vyqB?	NELVeoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESwN\|Q2Oyd-MkS0NFM1PTN:L3G+
CCD18Co	NHfjfJVHfW6ldHnvckBCe3OjeR?=	Mme1NVAxKG6P	NW\hNpJRPDhiaB?=		MV;wdo9ud3SnczDSWW5ZOyCmZX3leIh6dGG2aX;uxsA>	MknXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MEO0OVMoRjJ2NECzOFU{RC:jPh?=
DLD-1	MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7CWW4xNTFyMECgcm0>	M{XVVVQ5KGh?		MmPybY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	NI\aN5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESwN\|Q2Oyd-MkS0NFM1PTN:L3G+
CCD18Co	M1X2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjiW2UxNTFyMECgcm0>	NI\zTXA1QCCq		NV\odo1ZcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>?	MnHUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MEO0OVMoRjJ2NECzOFU{RC:jPh?=
HepG2	MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmnWNlQhcA>?		NFHreW1KSzVyPUWyMlXjiIoQvF2=	Mo\nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|NEG2PFgoRjJ2M{SxOlg5RC:jPh?=
HEK293/pcDNA3.1	NXzWWoVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTBwMEC0xtExNjByMEOg{txO	M13Bb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mki0O\|g{Lz5{NEK4OFc5OzxxYU6=
HEK293/MRP1	NV7oc4V7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTBwMEW1xtExNjBzMkCg{txO	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ6NEe4N{c,OjR{OES3PFM9N2F-
Ramos	NX3qN\|U{SXCxcITvd4l{KEG\|c3H5	Mm\tNwKBkc7:TR?=	M2fDblQ5KGh?		NIXtcIFqdmS3Y3XzJFM1NjZnwsGxMlkzLSCjcH;weI9{cXN?	NGjLdI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK1OlQ6OSd-MkSyOVY1QTF:L3G+
NCI-H1299/pcDNA3	MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NF\tPZUxNTJyIH7N	NWLUeY5JQTZiaB?=		MmTvbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF5N{CxNkc,OjRzN{ewNVI9N2F-
H1299/ICAM-3	M1jwZWNmdGxiVnnhZoltcXS7IFHzd4F6	NVGyNVZxOC1{MDDuUS=>	NYfQTWtKQTZiaB?=		M4fwe4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	NEf1XVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3O\|AyOid-MkSxO\|cxOTJ:L3G+
NCI-H1299/pcDNA3	NUXYT2tDTnWwY4Tpc44hSXO\|YYm=	NF7obXoyNzVxMUCvNlDDqG6P	MlrqPVYhcA>?		Mkf0bY5lfWOnczDjcIVifmGpZTDv[kBk[XOyYYPld{0{NCB6LDC5MEBidmRiUFHSVC=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF5N{CxNkc,OjRzN{ewNVI9N2F-
H1299/ICAM-3	MYLGeY5kfGmxbjDBd5NigQ>?	MY[xM\|UwOTBxMkFCpI5O	NHvhbHI6PiCq		NXG0Uo1rcW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1\|LDC4MEA6NCCjbnSgVGFTWA>?	NU\uXHNHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO\|cxOTJpPkK0NVc4ODF{PD;hQi=>
W1	NHjhdJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXJZ\|NKSzVyPUCuNFA{OiEQvF2=	NXX5PFZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFAyPzZpPkK0NVQxOTd4PD;hQi=>
W1VR	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXvTWM2OD1yLkC1OkDPxE1?	NYXLdZg1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFAyPzZpPkK0NVQxOTd4PD;hQi=>
K562	NIHKb\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\FSolKSzVyPUCuNFMzKMLzIECuNFAyKCEQvF2=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF\|NUmzO{c,OjRzM{W5N\|c9N2F-
K562/ADR	MkL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LWTGlEPTB;Mz6yOlEhyrFiMD60NVIh\|ryP	NUL0O5g{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN\|U6OzdpPkK0NVM2QTN5PD;hQi=>
K562	M2r2eGFxd3C2b4Ppd{BCe3OjeR?=	NU\1OnNCOC5\|IN88US=>	Mnm4NlQhcA>?		M13Neolv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl?	M3H5XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUO1PVM4Lz5{NEGzOVk{PzxxYU6=
K562/ADR	M13QOmFxd3C2b4Ppd{BCe3OjeR?=	MoPLN{DPxE1?	MlHTNlQhcA>?		M{fZeYlv\HWlZYOgZZBweHSxc3nz	NHLS[3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGzOVk{Pyd-MkSxN\|U6Ozd:L3G+
A549	NXflVJRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkeyTWM2OD1yLkGwJOKyKDBwMEOg{txO	M3HKXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUexNFc2Lz5{M{m3NVA4PTxxYU6=
K562	MmSwR4VtdCCYaXHibYxqfHliQYPzZZk>	MYGzMlc26oDVNkFCpI5O	M3LJVlczyqCqwrC=		NFPMcmdqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	M1jvTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEe3NlI{Lz5{M{i3O\|IzOzxxYU6=
lucena	MnK2R4VtdCCYaXHibYxqfHliQYPzZZk>	MmPCN{44PeLCk{[wxsBvVQ>?	M3L1WVczyqCqwrC=		NYLreVRDdm9iZX\m[YN1	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh5N{KyN{c,OjN6N{eyNlM9N2F-
FEPS	MkfKR4VtdCCYaXHibYxqfHliQYPzZZk>	M1\lOVMvPzYkgKO2NOKhdk1?	MmK3O\|LDqGkEoB?=		Momwco8h\W[oZXP0	M{HJ[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEe3NlI{Lz5{M{i3O\|IzOzxxYU6=
A2780	NF;HeWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTNwNTDtUS=>	NIf5TGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyPVIxOyd-MkO4NlkzODN:L3G+
ACHN	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXFU2JjUUN3MEywMlEhdU1?	NX22eGZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NlkzODNpPkKzPFI6OjB\|PD;hQi=>
U-937	NXqxZXY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRDN2IH7N	MlHXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MkmyNFMoRjJ\|OEK5NlA{RC:jPh?=
Jurkat	MXjBdI9xfG:\|aYOgRZN{[Xl?	MWS1xsDPxGdxbX\|CpC=>	MWGyOEBp		M4e5[4lv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl?	NX\Wb456RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NVA1ODlpPkKzPFExPDB7PD;hQi=>
Jurkat	NYTNNZR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PmdVXDqM7:Zz;tcOKh	MWKyOEBp		M4TFdIFzemW\|dDDKeZJs[XRiY3XscJMhcW5iR{KvUUBxcGG\|ZR?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzhzMESwPUc,OjN6MUC0NFk9N2F-
Hep-2	NGnmd\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jpXmlEPTB;MD6wOOKyOC5yMTFOwG0>	NG\Gb409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e4NFQzPCd-MkO3PFA1OjR:L3G+
Hep-2/v	M3HUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDwTWM2OD1zLklCtVAvOjBizszN	MmLJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OEC0NlQoRjJ\|N{iwOFI1RC:jPh?=
SGC-7901	NXTuNFViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2ixS\|AuOTBizsznM41t	MmLYNlQwPDhxN{KgbC=>		MmXmbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	NVTxZ5J{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFM2PzJpPkKzO\|Q{PTd{PD;hQi=>
SGC-7901/VCR	NWGwbGsyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\5VIoxNTFyIN88[{9udA>?	Mnu0NlQwPDhxN{KgbC=>		NHq5[VNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	M13KUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{SzOVczLz5{M{e0N\|U4OjxxYU6=
SGC-7901	MWPBdI9xfG:\|aYOgRZN{[Xl?				Ml7zbY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgQ>?	M2LyNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{SzOVczLz5{M{e0N\|U4OjxxYU6=
SGC-7901/VCR	MWPBdI9xfG:\|aYOgRZN{[Xl?				MnT6bY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgQ>?	NIfzb4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0N\|U4Oid-MkO3OFM2PzJ:L3G+
KB-3-1	M{fNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTFwNk[gxtEhOC5zNkKg{txO	Mmf6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4N{O0OFUoRjJ\|NkezOFQ2RC:jPh?=
KB-C2	MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTJyMj61OkDDuSB2Mj60PFEh\|ryP	NFnvcHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[3N\|Q1PSd-MkO2O\|M1PDV:L3G+
KB-3-1	MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XWc2lEPTB;MT6yOkDDuSByLkCyO{DPxE1?	NHLpUlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[3N\|Q1PSd-MkO2O\|M1PDV:L3G+
KB-V1	NUXnPZMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoT5TWM2OD1{MEiuPFUhyrFiMkCuOEDPxE1?	M324VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkezOFQ2Lz5{M{[3N\|Q1PTxxYU6=
HEK293/pcDNA3.1	M{fqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLUbXNqUUN3ME2yOE4yKMLzIECuNlA1KM7:TR?=	NEXQRXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[3N\|Q1PSd-MkO2O\|M1PDV:L3G+
HEK293/ABCB1	MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTN3MUKuPEDDuSB\|N{iuN\|kyKM7:TR?=	Mk\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4N{O0OFUoRjJ\|NkezOFQ2RC:jPh?=
A549/EGFP	MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX6wMlAyNTFyMECg{txO			Mm\0TWM2OD16Nj63JOKyKDJ7LkGg{txO	NV:4[llbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2N\|QzQDJpPkKzOlM1Ojh{PD;hQi=>
A549/Slug	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjBSWgxNjBzLUGwNFAh\|ryP			NWD5NVBzUUN3ME25MlchyrFiMz6xJO69VQ>?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ\|NEK4Nkc,OjN4M{SyPFI9N2F-
JFCR39	M4LJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVSxJOK2VQ>?	MknRNlQhcA>?	NIXjc3BFVVOR	NV6zfXVMdWG{a3XkcJkhcW6lcnXhd4V{KHSqZTDueY1j\XJib3[gS\|IwVSCyaHHz[UBk\Wyucx?=	MojhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3OUiyO\|YoRjJ\|NUm4Nlc3RC:jPh?=
A549	MWHGeY5kfGmxbjDBd5NigQ>?	NUHBPYpoOTByIH7N	NYDFOXBMOTZiaB?=	NHXIWm5FVVOR	NHqzeWxt\WGmczD0c{BiKGyxc4Ogc4YhdWmlcn;0eYJ2dGW\|	M{TQdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUm4Nlc3Lz5{M{W5PFI4PjxxYU6=
SGC7901	Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETXOGNKSzVyPUGuNlbjiIoEsfMAjVAvOTFizsznM41t	Mnu1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkS0PFIoRjJ\|NU[0OFgzRC:jPh?=
SGC7901/LV-NC	Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHiTWM2OD1zLke35qCKyrIkgJmwMlE3KM7:Zz;tcC=>	M3XBT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[0OFgzLz5{M{W2OFQ5OjxxYU6=
SGC7901/LV-SGO1	M1XEXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTRwM{dihKnDueLCiUCuN\|ch\|rypL33s	MonSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkS0PFIoRjJ\|NU[0OFgzRC:jPh?=
SGC7901/VCR	MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rzWGlEPTN;MkCuOVPjiIoEsfMAjVEvQTZizsznM41t	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4NES4Nkc,OjN3NkS0PFI9N2F-
SGC7901/VCR-NC	NFX5dmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{f5UmlEPTB;MUmuPFbjiIoEsfMAjVIvODFizsznM41t	M4LjbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[0OFgzLz5{M{W2OFQ5OjxxYU6=
SGC7901/VCR-si-SGO1	MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvvOoVKSzVyPU[uNVjjiIoEsfMAjVEvODNizsznM41t	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4NES4Nkc,OjN3NkS0PFI9N2F-
SGC7901/ADR	M3;TeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2P0XWlEPTB;Nz64OgKBkcLz4pEJNE43PCEQvHevcYw>	M3zrTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[0OFgzLz5{M{W2OFQ5OjxxYU6=
SGC7901/ADR-NC	MkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moj5TWM2OD16Lkmz5qCKyrIkgJmwMlY5KM7:Zz;tcC=>	NYXVVoFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlQ1QDJpPkKzOVY1PDh{PD;hQi=>
SGC7901/ADR-si-SGO1	NYPISWJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFz3VmtKSzVyPUOuOFbjiIoEsfMAjVAvOjlizsznM41t	MkKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkS0PFIoRjJ\|NU[0OFgzRC:jPh?=
SH-SY5Y	NFzsV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV2wMlAxOS1zMDFOwG0>	M2jzTFI1KGh?		NFO3UFFKSzVyPUCuNVE{yrFyLkCxNkDPxE1?	M4izOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUK5NFY2Lz5{M{GyPVA3PTxxYU6=
SH-SY5Y	NHjaWG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnKR2YxNjByMT2xNEDPxE1?	MVG0PEBp		M2njbWlEPTB;MD6wO\|jDuTBwMEC5JO69VQ>?	MnP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzMkmwOlUoRjJ\|MUK5NFY2RC:jPh?=
SH-SY5Y	M4jDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYCwMlAxOS1zMDFOwG0>	MVS3NkBp		MmT3TWM2OD1yLkC1NeKyOC5yMEig{txO	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF{OUC2OUc,OjNzMkmwOlU9N2F-
SH-SY5Y	NUTS[GozSXCxcITvd4l{KEG\|c3H5	NXfRb2NjOC5zIN88US=>	M{XpfVAuOjRiaB?=		NYTIcGpucW6mdXPld{BieG:ydH;zbZMhd2ZiU1itV3k2YSClZXzsd{Bnd2yub4fpcoch[2WubDDjfYNt\SCjcoLld5Qh[XRidHjlJGczN01icHjhd4U>	NUTqdHRERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxNlkxPjVpPkKzNVI6ODZ3PD;hQi=>
SH-SY5Y	NH\jPFNCeG:ydH;zbZMhSXO\|YYm=	M1fzPFAvOSEQvF2=	MoHYNE0zPCCq		MVfpcoR2[2W\|IH3peI91cWNiYYLy[ZN1yqB?	M4i1bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUK5NFY2Lz5{M{GyPVA3PTxxYU6=
LNCAP	MYLDfZRwfG:6aXPpeJkh[XO\|YYm=		NUnocHhZPzJiaILz		NEPRbIFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNVkODUDDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUAxNjByMkmg{txONg>?	Mn24QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB5M{K4NFkoRjJyN{OyPFA6RC:jPh?=
LNCAP	NIXnTXpEgXSxdH;4bYNqfHliYYPzZZk>		M4XWUVczKGi{cx?=		NFm0[pdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNVkODUDDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUAxNjByNkGg{txONg>?	M{\qRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkG1N\|Q5Lz5{M{KxOVM1QDxxYU6=
PC3	MoLRR5l1d3SxeHnjbZR6KGG\|c3H5		MnvSO\|IhcHK\|		NEjqXHdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JIFt[W2jcjDicJVmKGG\|c3H5MEBKSzVyIE2gNE4xOTFizszNMi=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODd\|MkiwPUc,OjB5M{K4NFk9N2F-
PC3	MlrvR5l1d3SxeHnjbZR6KGG\|c3H5		NV7TWpViPzJiaILz		MlvtR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IECuNFE2KM7:TT6=	NYri[3M2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNVU{PDhpPkKzNlE2OzR6PD;hQi=>
PC3	NFPTdGtEgXSxdH;4bYNqfHliYYPzZZk>		MYS3NkBpenN?		MoK1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hOC5yMUWzJO69VS5?	NVztOmE6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PFkzQTFpPkKzOFg6OjlzPD;hQi=>
NFF	M2fqSWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NEiydXM4OiCqcoO=		NFjSSFNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPTkZiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliYXzhcYFzKGKudXWgZZN{[XluIFnDOVAhRSByLkCxOlkh\|ryPLh?=	MkKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OEmyPVEoRjJ\|NEi5NlkyRC:jPh?=
NFF	M{LEdGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NHz5[ZQ4OiCqcoO=		NHTRcJFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPTkZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JIFt[W2jcjDicJVmKGG\|c3H5MEBKSzVyIE2gNE4xOTdizszNMi=>	M33NflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkG1N\|Q5Lz5{M{KxOVM1QDxxYU6=
A549	M4DV[mN6fG:2b4jpZ4l1gSCjc4PhfS=>		M{\Q[VczKGi{cx?=		NYrsdnN{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUAxNjB{IN88UU4>	MnTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{MUWzOFgoRjJ\|MkG1N\|Q5RC:jPh?=
KB	MlLmR5l1d3SxeHnjbZR6KGG\|c3H5		NYe1W5Y{PzJiaILz		NIe1R3lEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSiClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gNE4xOiEQvF2u	M{nkbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUKyPVU{Lz5{NkWyNlk2OzxxYU6=
PC3	M3HxZmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M4LpVVQ5KGi{cx?=		M1rjR2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkCyO\|Yh\|ryPLh?=	MlPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyM{izNlMoRjJ6MEO4N\|I{RC:jPh?=
HEK	MUjDfZRwfG:6aXPpeJkh[XO\|YYm=		MU[3NkBpenN?		MWLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDISWsh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR\|UxKD1iMD6wN\|Eh\|ryPLh?=	NHK4foc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KxOVM1QCd-MkOyNVU{PDh:L3G+
HeLa	MmPLR5l1d3SxeHnjbZR6KGG\|c3H5		MoDqO\|IhcHK\|		NHTFNHBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR\|UxKD1iMD6wN\|U5KM7:TT6=	NFG4XXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S4PVI6OSd-MkO0PFkzQTF:L3G+
HeLa	NVvnZ4ZvS3m2b4TvfIlkcXS7IHHzd4F6		NV21W4R1PzJiaILz		MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IECuNFM3KM7:TT6=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJzNUO0PEc,OjN{MUWzOFg9N2F-
BT549	NYS0NpFJSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NVP3[GpEPDhiaILz		NWiyO5dHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDCWFU1QSClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xPTR5MjFOwG0v	M{DUO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEO4N\|I{Lz5{OECzPFMzOzxxYU6=
DU145	M2nuSmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M4W3RlQ5KGi{cx?=		NIe2bW9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTVNVQ2KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlA4OjNizszNMi=>	MkjHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyM{izNlMoRjJ6MEO4N\|I{RC:jPh?=
Leukemia cells	MYjBcpRqfHWvb4KgZZN{[Xl?		M2T3Z\|Q5KGi{cx?=		MoSwRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTHX1b4VucWFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFAvOSEQvF2u	NFrj[5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
Leukemia cells	NVLVNo1YSW62aYT1cY9zKGG\|c3H5		NWjTeWN3PDhiaILz		Mn\NRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTHX1b4VucWFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0liPTCwMlEh\|ryPLh?=	NUnjVowzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
Colon cancer cells	NEDGV3dEgXSxdH;4bYNqfHliYYPzZZk>				M3LuVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJINwdG:wIHPhcoNmeiClZXzsd{whT0l3MDC9JFAvOSEQvF2u	NFHtRpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
Leukemia cells	NV;pRYc2S3m2b4TvfIlkcXS7IHHzd4F6				M13yPGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIxmfWunbXnhJINmdGy\|LDDHTVUxKD1iMD6xJO69VS5?	M3;sZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
Colon cancer cells	M2fVTGFvfGm2dX3vdkBie3OjeR?=		MVW0PEBpenN?		MoGxRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ3;sc44h[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkGg{txONg>?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
Colon cancer cells	MWDBcpRqfHWvb4KgZZN{[Xl?		MUe0PEBpenN?		NGLCVmxCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDc4xwdiClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2khRSByLkGg{txONg>?	M3jPbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
Leukemia cells	MmD1RY51cXS3bX;yJIF{e2G7				NYnWNJhtSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhdGW3a3XtbYEh[2WubIOsJGdKPTBiPTCwMlEh\|ryPLh?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV3OUKwOUc,OTd3NUmyNFU9N2F-
Colon cancer cells	M4nMcGFvfGm2dX3vdkBie3OjeR?=				NFe5Z5NCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBkd2yxbjD0eY1weiClZXzsd{whT0l3MDC9JFAvOSEQvF2u	NGnC[5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1PVIxPSd-MUe1OVkzODV:L3G+
Leukemia cells	NWDwUJNZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4nuOlQ5KGi{cx?=		NYf4PWJ6T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hdGW3a3XtbYEh[2WubIOgZYZ1\XJiNEigbJJ{NCCJSUWwJF0hOC5zIN88UU4>	MojGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
Colon cancer cells	M4PWXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUm0PEBpenN?		M3PrTmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJINwdG:wIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkGg{txONg>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW5PUc,OjB4OES1PVk9N2F-
Leukemia cells	MWXDfZRwfG:6aXPpeJkh[XO\|YYm=		M1TR[FQ5KGi{cx?=		M2fyfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIxmfWunbXnhJINmdGy\|IHHmeIVzKDR6IHjyd{whT0l3MDC9JFAvOSEQvF2u	M135R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
Colon cancer cells	NVP6VVJjS3m2b4TvfIlkcXS7IHHzd4F6		MnXUOFghcHK\|		NUHwNmtVS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4h[2:ub36gZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuNUDPxE1w	M4XDb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
Leukemia cells	NHvGUHdEgXSxdH;4bYNqfHliYYPzZZk>		MWi0PEBpenN?		NX2ySZB5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdGW3a3XtbYEh[2WubIOgZYZ1\XJiNEigbJJ{NCCJSUWwJF0hOC5zIN88UU4>	NELQeJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
Colon cancer cells	M4XoRWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MX60PEBpenN?		NEXmcWREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEV0yRTjDj[YxteyCjZoTldkA1QCCqcoOsJGdKPTBiPTCwMlEh\|ryPLh?=	M3PZb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkizOFMxLz5{MkK4N\|Q{ODxxYU6=
MDA-MB-231	M2XSTmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M3zLPFQ5KGi{cx?=		NGjrZ3dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMUG2OkDPxE1w	MnHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyM{izNlMoRjJ6MEO4N\|I{RC:jPh?=
central nervous system cancer cells	NETndZBEgXSxdH;4bYNqfHliYYPzZZk>				M2rGcGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJINmdnS{YXygcoVzfm:3czDzfZN1\W1iY3HuZ4VzKGOnbHzzMEBIUTVyIE2gNE4yOjV6OTFOwG0v	NGnve5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
prostate cancer cells	NE\Sb\|NEgXSxdH;4bYNqfHliYYPzZZk>				Ml7qR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdJJwe3SjdHWgZ4Fv[2W{IHPlcIx{NCCJSUWwJF0hOC5zMkW4PUDPxE1w	NF\VOYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
CNS	NHjTb4VCdnSrdIXtc5Ih[XO\|YYm=		NH\E[IE1QCCqcoO=		NWDxfnJ2SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gR25UKGOjbnPldkBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6xNlU5QSEQvF2u	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
prostate cancer cells	M1\sbGFvfGm2dX3vdkBie3OjeR?=		Mnm3OFghcHK\|		M3PNTGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIIDyc5N1[XSnIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4yOjV6OTFOwG0v	NEPl[lc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
CNS	MYfBcpRqfHWvb4KgZZN{[Xl?				M4TYXGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGNPWyC2dX3vdkBk\WyuczygS2k2OCB;IECuNVI2QDlizszNMi=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV3OUKwOUc,OTd3NUmyNFU9N2F-
prostate cancer cells	MXHBcpRqfHWvb4KgZZN{[Xl?				NYTpc5VMSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QheHKxc4TheIUhfHWvb4KgZ4VtdHNuIFfJOVAhRSByLkGyOVg6KM7:TT6=	NVjjWZhMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
CNS	NX7GVpVlSW62aYT1cY9zKGG\|c3H5		MnnEOFghcHK\|		Mkn3RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ17TJINidmOncjDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSTC9JFAvOTNizszNMi=>	Mlz4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
prostate cancer cells	NX[wTmFKSW62aYT1cY9zKGG\|c3H5		NWTJe2ZHPDhiaILz		MmflRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5icILvd5RifGViY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGdKKD1iMD6xN{DPxE1w	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
prostate cancer cells	M{O2cWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWS0PEBpenN?		NHLuXndIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBxem:\|dHH0[UBk[W6lZYKgZ4VtdHNiYX\0[ZIhPDhiaILzMEBIUTVyIE2gNE4yOyEQvF2u	NWfReZhvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFQ2QTlpPkKwOlg1PTl7PD;hQi=>
CNS	NGf6foFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2fWcFQ5KGi{cx?=		NWXXdVNtT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hS06VIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkGzJO69VS5?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW5PUc,OjB4OES1PVk9N2F-
CNS	NFjMVppEgXSxdH;4bYNqfHliYYPzZZk>		MXW0PEBpenN?		MlHVR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR25UKGOjbnPldkBk\WyuczDh[pRmeiB2ODDodpMtKEeLNUCgQUAxNjF\|IN88UU4>	NG\nV\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0O\|c1QSd-MkS3OFc4PDl:L3G+
prostate cancer cells	M4D1SWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M2XrelQ5KGi{cx?=		MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDwdo9{fGG2ZTDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDHTVUxKD1iMD6xN{DPxE1w	NXv2cZQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFc4PDlpPkK0O\|Q4PzR7PD;hQi=>
prostate cancer cells	M3[1T2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M3LkelQ5KGi{cx?=		M{\a[WN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJBzd3O2YYTlJINidmOncjDj[YxteyCjZoTldkA1QCCqcoOsJGdKPTBiPTCwMlE{KM7:TT6=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
CNS	NWnvb\|NmS3m2b4TvfIlkcXS7IHHzd4F6		MoqxOFghcHK\|		MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDUnMh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{whT0l3MDC9JFAvOTNizszNMi=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
Melanoma cells	Mmm1RY51cXS3bX;yJIF{e2G7		MonDOFghcHK\|		NUPnSoRDSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUYVt[W6xbXGgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDBwMUW4OFkh\|ryPLh?=	MnKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
Melanoma cells	NFjxTZREgXSxdH;4bYNqfHliYYPzZZk>				NEe0VVNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBu\Wyjbn;tZUBk\WyuczygS2k2OCB;IECuNVU5PDlizszNMi=>	M3LIUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
Melanoma cells	MkLnRY51cXS3bX;yJIF{e2G7				MoCyRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgcYVt[W6xbXGgZ4VtdHNuIFfJOVAhRSByLkG1PFQ6KM7:TT6=	NHTvV3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1PVIxPSd-MUe1OVkzODV:L3G+
Melanoma cells	NWDGU5RlSW62aYT1cY9zKGG\|c3H5		MVm0PEBpenN?		Ml;URY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTXXsZY5wdWFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0liPTCwMlE3KM7:TT6=	M1O3ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
Melanoma cells	M2\1Xmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MYnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDt[Yxidm:vYTDj[YxteyCjZoTldkA1QCCqcoOsJGdKPTBiPTCwMlE3KM7:TT6=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW5PUc,OjB4OES1PVk9N2F-
Melanoma cells	NWq4XGdnS3m2b4TvfIlkcXS7IHHzd4F6		NXzseWlZPDhiaILz		NFrCR5pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBu\Wyjbn;tZUBk\WyuczDh[pRmeiB2ODDodpMtKEeLNUCgQUAxNjF4IN88UU4>	NWrJWHpYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFc4PDlpPkK0O\|Q4PzR7PD;hQi=>
Melanoma cells	NWHxZ4E3S3m2b4TvfIlkcXS7IHHzd4F6		NWHYU4M3PDhiaILz		MmHLR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gcYVt[W6xbXGgZ4VtdHNiYX\0[ZIhPDhiaILzMEBIUTVyIE2gNE4yPiEQvF2u	MmriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{OEO0N\|AoRjJ{MkizOFMxRC:jPh?=
A549	NGn4bXlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NF34d\|k1QCCqcoO=		M3:4PWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xO\|E2KM7:TT6=	MkPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyM{izNlMoRjJ6MEO4N\|I{RC:jPh?=
NSCLC	NULDVGM5SW62aYT1cY9zKGG\|c3H5		M{DlXlQ5KGi{cx?=		MoDKRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTmPDUGMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2khRSByLkK1JO69VS5?	M1;JU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
NSCLC	MnXBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NG\xXmk1QCCqcoO=		MX\Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOV2NNSyClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkK1JO69VS5?	NUnpV25XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFQ2QTlpPkKwOlg1PTl7PD;hQi=>
NSCLC	NX\he4p4S3m2b4TvfIlkcXS7IHHzd4F6		NXq5dlRmPDhiaILz		M2PZUWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5US0yFIHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuNlUh\|ryPLh?=	NXPlfHNnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyPFM1OzBpPkKyNlg{PDNyPD;hQi=>
NSCLC	MoPKR5l1d3SxeHnjbZR6KGG\|c3H5		NFzBO3g1QCCqcoO=		NHvJVmFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPW0OOQzDj[YxteyCjZoTldkA1QCCqcoOsJGdKPTBiPTCwMlI2KM7:TT6=	NWfaeoRJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFc4PDlpPkK0O\|Q4PzR7PD;hQi=>
NSCLC	NXHPRY1MSW62aYT1cY9zKGG\|c3H5				MV3BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDOV2NNSyClZXzsd{whT0l3MDC9JFAvOjVzMUmg{txONg>?	NEC5RW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1PVIxPSd-MUe1OVkzODV:L3G+
NSCLC	NWfOVHRYSW62aYT1cY9zKGG\|c3H5		M2G4[\|Q5KGi{cx?=		NUDRboRHSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUnNEVENiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFAvOjVzMUmg{txONg>?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
Non-small cell lung carcinoma cells	MoPHR5l1d3SxeHnjbZR6KGG\|c3H5				NWjZWodJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVm:wLYPtZYxtKGOnbHygcJVv\yClYYLjbY5wdWFiY3XscJMtKEeLNUCgQUAxNjJ3MUG5JO69VS5?	Moj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3OUiwNVgoRjF6NUm4NFE5RC:jPh?=
ovarian cancer cells	NY\ZXWxvS3m2b4TvfIlkcXS7IHHzd4F6				MmnTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gc5ZiemmjbjDjZY5k\XJiY3XscJMtKEeLNUCgQUAxNjNzNkKzJO69VS5?	MluxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3OUiwNVgoRjF6NUm4NFE5RC:jPh?=
renal cancer cells	MnfER5l1d3SxeHnjbZR6KGG\|c3H5				NYHjSm5RS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hemWwYXygZ4Fv[2W{IHPlcIx{NCCJSUWwJF0hOC5\|MU[yN{DPxE1w	NV3v[Y5kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
breast cancer cells	MV\DfZRwfG:6aXPpeJkh[XO\|YYm=				NV7oUWpJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4h[nKnYYP0JINidmOncjDj[YxteyxiR1m1NEA:KDBwM{G2NlMh\|ryPLh?=	M3rCOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
ovarian cancer cells	MYrBcpRqfHWvb4KgZZN{[Xl?		MVe0PEBpenN?		MUDBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCxdnHybYFvKGOjbnPldkBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6zNVYzOyEQvF2u	Mo\vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
renal cancer cells	NH3LV4JCdnSrdIXtc5Ih[XO\|YYm=		NYHDTYxmPDhiaILz		MoLTRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5icnXuZYwh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkOxOlI{KM7:TT6=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
breast cancer cells	MnXiRY51cXS3bX;yJIF{e2G7		NXzTcmdQPDhiaILz		NFvIZotCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDCdoVie3RiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlMyPjJ\|IN88UU4>	NEXTOFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
renal cancer cells	NV23ZYhxSW62aYT1cY9zKGG\|c3H5				M1Oxc2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JJJmdmGuIIT1cY9zKGOnbHzzMEBIUTVyIE2gNE4{OTZ{MzFOwG0v	NFXvdoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1PVIxPSd-MUe1OVkzODV:L3G+
ovarian cancer cells	MUDBcpRqfHWvb4KgZZN{[Xl?				NYXzSnVRSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5Qhd3[jcnnhckB1fW2xcjDj[YxteyxiR1m1NEA:KDBwM{G2NlMh\|ryPLh?=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV3OUKwOUc,OTd3NUmyNFU9N2F-
breast cancer cells	MX3BcpRqfHWvb4KgZZN{[Xl?				MkXGRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgZpJm[XO2IIT1cY9zKGOnbHzzMEBIUTVyIE2gNE4{OTZ{MzFOwG0v	NYPWXJUzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
ovarian cancer cells	Ml\0RY51cXS3bX;yJIF{e2G7		MYm0PEBpenN?		M3\wWmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIH;2ZZJq[W5iY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGdKKD1iMD6zNkDPxE1w	NXv3VI82RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
renal cancer cells	NG\rWW5CdnSrdIXtc5Ih[XO\|YYm=		NEHLNWQ1QCCqcoO=		MVPBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiC{ZX7hcEBk[W6lZYKgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1mgQUAxNjN{IN88UU4>	MluwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
breast cancer cells	Moq0RY51cXS3bX;yJIF{e2G7		NUXyNJVzPDhiaILz		MUDBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCEcnXhd5Qh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJJF0hOC5\|MjFOwG0v	NIDwN\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
renal cancer cells	MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NIC2Onc1QCCqcoO=		MVHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDy[Y5idCClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{NCCJSUWwJF0hOC5\|MjFOwG0v	NVvoSJVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFQ2QTlpPkKwOlg1PTl7PD;hQi=>
breast cancer cells	M1P3T2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3\Sb\|Q5KGi{cx?=		NYDaR41ET3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[nKnYYP0JINidmOncjDj[YxteyCjZoTldkA1QCCqcoOsJGdKPTBiPTCwMlMzKM7:TT6=	NU\oPYpoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFQ2QTlpPkKwOlg1PTl7PD;hQi=>
ovarian cancer cells	NGDFfXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHL5e2E1QCCqcoO=		M2TOWmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG93[XKrYX6gZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuN\|Ih\|ryPLh?=	NEm5fW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4OFU6QSd-MkC2PFQ2QTl:L3G+
breast cancer cells	M1;uVmN6fG:2b4jpZ4l1gSCjc4PhfS=>		Mnq2OFghcHK\|		NFnHNGpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuN\|Ih\|ryPLh?=	NG\CRpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0O\|c1QSd-MkS3OFc4PDl:L3G+
renal cancer cells	M1\4ZWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1PiWVQ5KGi{cx?=		M3PkemN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJJmdmGuIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkOyJO69VS5?	M{W2WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
ovarian cancer cells	NFT5dHJEgXSxdH;4bYNqfHliYYPzZZk>		M17jVVQ5KGi{cx?=		MojyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gc5ZiemmjbjDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDHTVUxKD1iMD6zNkDPxE1w	M331dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
renal cancer cells	M17rWWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M2L2[FQ5KGi{cx?=		NGH5bHJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBz\W6jbDDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDHTVUxKD1iMD6zNkDPxE1w	NIDGc489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
ovarian cancer cells	NIL6e5FEgXSxdH;4bYNqfHliYYPzZZk>		MoruOFghcHK\|		MmjhR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gc5ZiemmjbjDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDHTVUxKD1iMD6zNkDPxE1w	NF2zNJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
breast cancer cells	NWrMfpI1S3m2b4TvfIlkcXS7IHHzd4F6		M{TWVlQ5KGi{cx?=		MWDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDidoVie3RiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiR1m1NEA:KDBwM{Kg{txONg>?	NEnYe4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
Lu1	NUOwVFhOS3m2b4TvfIlkcXS7IHHzd4F6		NYXUcFlCPzJiaILz		NWqzRZRlS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVHVzIHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjR6IN88UU4>	NGLI[lI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkWyNlk2Oyd-Mk[1NlI6PTN:L3G+
MCF7	NGi2fmJEgXSxdH;4bYNqfHliYYPzZZk>		NXzMbpRwPzJiaILz		M2PMU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFAvPTFizszNMi=>	NYrPO4xPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1NlI6PTNpPkK2OVIzQTV\|PD;hQi=>
HepG2	M3T2RmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M36zclczKGi{cx?=		MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gNE43QSEQvF2u	M2\lelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUKyPVU{Lz5{NkWyNlk2OzxxYU6=
COLON	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGTleVc1QCCqcoO=		NVLOR49TT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[2:ub36gZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iMz65PEDPxE1w	M3rhOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNki0OVk6Lz5{ME[4OFU6QTxxYU6=
COLON	NHzV[\|NEgXSxdH;4bYNqfHliYYPzZZk>		M1f2Z\|Q5KGi{cx?=		MkH0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZ49td25iY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiVFfJJF0hOy57ODFOwG0v	NFPMPZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0O\|c1QSd-MkS3OFc4PDl:L3G+
COLON	M3rKTWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MkTUOFghcHK\|		NWHzPXF[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0:OT16gZ4VtdHNiYX\0[ZIhPDhiaILzMEBVT0liPTCzMlk5KM7:TT6=	MoDPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{OEO0N\|AoRjJ{MkizOFMxRC:jPh?=
COLON	NUPUSJViS3m2b4TvfIlkcXS7IHHzd4F6				MkjvR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZ49td25iY3HuZ4VzKGOnbHzzMEBVT0liPTCzMlk5OTB5IN88UU4>	NEnRVXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
COLON	NX3OT5A1SW62aYT1cY9zKGG\|c3H5		MnHMOFghcHK\|		MlvpRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ3;sc44h[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIGTHTUA:KDNwOUixNFch\|ryPLh?=	MnzlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
COLON	NGDGRZJCdnSrdIXtc5Ih[XO\|YYm=				MX;BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDjc4xwdiC2dX3vdkBk\WyuczygWGdKKD1iMz65PFExPyEQvF2u	NVK0T\|MyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
central nervous system cancer cells	MXnDfZRwfG:6aXPpeJkh[XO\|YYm=				MYjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDj[Y51emGuIH7ldpZwfXNic4nzeIVuKGOjbnPldkBk\WyuczygWGdKKD1iNj6zNFk2PyEQvF2u	MkTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3OUiwNVgoRjF6NUm4NFE5RC:jPh?=
prostate cancer cells	MUHDfZRwfG:6aXPpeJkh[XO\|YYm=				NHu0e4hEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBxem:\|dHH0[UBk[W6lZYKgZ4VtdHNuIGTHTUA:KDZwM{C5OVch\|ryPLh?=	NYPvOll2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
CNS	NX3jfm9oSW62aYT1cY9zKGG\|c3H5		M2GwUFQ5KGi{cx?=		NH6zTnNCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDUnMh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIGTHTUA:KDZwM{C5OVch\|ryPLh?=	M3n3[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
prostate cancer cells	M4q0eGFvfGm2dX3vdkBie3OjeR?=		NVzRXFBLPDhiaILz		M4fKO2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIIDyc5N1[XSnIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBVT0liPTC2MlMxQTV5IN88UU4>	MnPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
CNS	M{DCemFvfGm2dX3vdkBie3OjeR?=				NWPZO2s6SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhS06VIIT1cY9zKGOnbHzzMEBVT0liPTC2MlMxQTV5IN88UU4>	M2TRTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUW5NlA2Lz5zN{W1PVIxPTxxYU6=
prostate cancer cells	NVTNSpMzSW62aYT1cY9zKGG\|c3H5				NVPKZm9tSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QheHKxc4TheIUhfHWvb4KgZ4VtdHNuIGTHTUA:KDZwM{C5OVch\|ryPLh?=	NWPme\|FbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
prostate cancer cells	MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M13kfFQ5KGi{cx?=		MoSwS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gdJJwe3SjdHWgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iNj6zNUDPxE1w	M4WxUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNki0OVk6Lz5{ME[4OFU6QTxxYU6=
CNS	M3vWbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NYTaTllqPDhiaILz		NVq1dYRVT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hS06VIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIGTHTUA:KDZwM{Gg{txONg>?	NH72XnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4OFU6QSd-MkC2PFQ2QTl:L3G+
CNS	M3HqWmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1TGTFQ5KGi{cx?=		NFr0OFJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEVlNiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiVFfJJF0hPi5\|MTFOwG0v	M3jlcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
prostate cancer cells	MlXmR5l1d3SxeHnjbZR6KGG\|c3H5		M4K0ZVQ5KGi{cx?=		NX7RZoV[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4heHKxc4TheIUh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{whXEeLIE2gOk4{OSEQvF2u	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
prostate cancer cells	Ml\KR5l1d3SxeHnjbZR6KGG\|c3H5		NYjrfnBsPDhiaILz		MlLHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdJJwe3SjdHWgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iNj6zNUDPxE1w	NF;WZo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
CNS	NIrMWplEgXSxdH;4bYNqfHliYYPzZZk>		MVK0PEBpenN?		M4n1eWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNPWyClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{NCCWR1mgQUA3NjNzIN88UU4>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
Melanoma cells	MnrOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlzPOFghcHK\|		NWHKNG5pT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hdWWuYX7vcYEh[2WubIOgZYZ1\XJiNEigbJJ{NCCWR1mgQUA4Njl2IN88UU4>	Mor5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
breast cancer cells	NXrw[mx{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MmKyOFghcHK\|		MlXHS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gZpJm[XO2IHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIGTHTUA:KDdwOUSg{txONg>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW5PUc,OjB4OES1PVk9N2F-
breast cancer cells	NIfXd3BEgXSxdH;4bYNqfHliYYPzZZk>		M4rwe\|Q5KGi{cx?=		NVPuN\|hKS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4h[nKnYYP0JINidmOncjDj[YxteyCjZoTldkA1QCCqcoOsJHRIUSB;IEeuPVQh\|ryPLh?=	M4Da[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
Melanoma cells	NUHBc2p6S3m2b4TvfIlkcXS7IHHzd4F6		NVPZVHdxPDhiaILz		NGTXVZlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBu\Wyjbn;tZUBk\WyuczDh[pRmeiB2ODDodpMtKFSJSTC9JFcvQTRizszNMi=>	NYr6WIdURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFc4PDlpPkK0O\|Q4PzR7PD;hQi=>
Melanoma cells	M374RmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1rqeFQ5KGi{cx?=		M13M[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI1mdGGwb33hJINmdGy\|IHHmeIVzKDR6IHjyd{whXEeLIE2gO{46PCEQvF2u	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
breast cancer cells	NELkUXlEgXSxdH;4bYNqfHliYYPzZZk>		MXy0PEBpenN?		M2fEVGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIJz\WG\|dDDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSB5Lkm0JO69VS5?	M33rOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkizOFMxLz5{MkK4N\|Q{ODxxYU6=
Melanoma cells	NVzSUYdtSW62aYT1cY9zKGG\|c3H5		MoHVOFghcHK\|		MYDBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPZXzhco9u[SClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBVT0liPTC3Mlk1OzJ6IN88UU4>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
Melanoma cells	MlPGR5l1d3SxeHnjbZR6KGG\|c3H5				M2rCcGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI1mdGGwb33hJINmdGy\|LDDUS2khRSB5Lkm0N\|I5KM7:TT6=	M{PpbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
breast cancer cells	M{[yUGN6fG:2b4jpZ4l1gSCjc4PhfS=>				NGq2W5JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIx{NCCWR1mgQUA4Njl2M{K4JO69VS5?	NU[5c3lZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
breast cancer cells	MlLpRY51cXS3bX;yJIF{e2G7		MYq0PEBpenN?		M3THW2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLy[YF{fCClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygWGdKKD1iNz65OFMzQCEQvF2u	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
Melanoma cells	NFXEeHBCdnSrdIXtc5Ih[XO\|YYm=				MXTBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDt[Yxidm:vYTDj[YxteyxiVFfJJF0hPy57NEOyPEDPxE1w	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV3OUKwOUc,OTd3NUmyNFU9N2F-
breast tumor cells	NFi1cW1CdnSrdIXtc5Ih[XO\|YYm=				MX;BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDidoVie3RidIXtc5Ih[2WubIOsJHRIUSB;IEeuPVQ{OjhizszNMi=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV3OUKwOUc,OTd3NUmyNFU9N2F-
NSCLC	Mki1RY51cXS3bX;yJIF{e2G7				M3e2XWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JG5US0yFIHPlcIx{NCCWR1mgQUAyPS56NEi5JO69VS5?	NFPOVlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1PVIxPSd-MUe1OVkzODV:L3G+
Leukemia cells	M2nyNmFvfGm2dX3vdkBie3OjeR?=		M4POVVQ5KGi{cx?=		MmnIRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTHX1b4VucWFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhXEeLIE2gNVUvQDR6OTFOwG0v	M{H1clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
NSCLC	MnziRY51cXS3bX;yJIF{e2G7		M1zPXlQ5KGi{cx?=		M2HIcWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7TR2xEKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJHRIUSB;IEG1Mlg1QDlizszNMi=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
Non-small cell lung carcinoma cells	NVjKW3pXS3m2b4TvfIlkcXS7IHHzd4F6				M4PMPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5wdi2\|bXHscEBk\WyuIHz1coch[2G{Y3nuc41iKGOnbHzzMEBVT0liPTCxOU45PDh7IN88UU4>	NUTQSWdXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
Leukemia cells	NVXTdFlFS3m2b4TvfIlkcXS7IHHzd4F6				NX3QSo5FS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdGW3a3XtbYEh[2WubIOsJHRIUSB;IEG1Mlg1QDlizszNMi=>	Mk\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3OUiwNVgoRjF6NUm4NFE5RC:jPh?=
Leukemia cells	NFvT[VZCdnSrdIXtc5Ih[XO\|YYm=				NUHlPVdySW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhdGW3a3XtbYEh[2WubIOsJHRIUSB;IEG1Mlg1QDlizszNMi=>	MkfXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3NUmyNFUoRjF5NUW5NlA2RC:jPh?=
NSCLC	NHHvclhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVm0PEBpenN?		MUHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOV2NNSyClZXzsd{Bi\nSncjC0PEBpenNuIGTHTUA:KDF3Lki1JO69VS5?	MoDtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
Leukemia cells	NF7UdppIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NH;iSWQ1QCCqcoO=		NF7tRYVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBt\XWtZX3pZUBk\WyuczDh[pRmeiB2ODDodpMtKFSJSTC9JFE2Njh3IN88UU4>	MmGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
NSCLC	M2\6b2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MXG0PEBpenN?		MnPiR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUnNEVENiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSBzNT64OUDPxE1w	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
Leukemia cells	MnTFR5l1d3SxeHnjbZR6KGG\|c3H5		M2DLdFQ5KGi{cx?=		MoTjR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gcIV2c2WvaXGgZ4VtdHNiYX\0[ZIhPDhiaILzMEBVT0liPTCxOU45PSEQvF2u	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
NSCLC	NHe2UmpEgXSxdH;4bYNqfHliYYPzZZk>		NFvYT3U1QCCqcoO=		M1;XcWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5US0yFIHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iMUWuPFUh\|ryPLh?=	M1q5OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
Leukemia cells	M3TkXGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MkXBOFghcHK\|		M1;PPGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIxmfWunbXnhJINmdGy\|IHHmeIVzKDR6IHjyd{whXEeLIE2gNVUvQDVizszNMi=>	NEL1[WU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
renal cancer cells	NGL0e4hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEn4XpQ1QCCqcoO=		MkXQS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gdoVv[WxiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiVFfJJF0hOTlwOUWg{txONg>?	M1;rZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNki0OVk6Lz5{ME[4OFU6QTxxYU6=
ovarian cancer cells	NGfGdlVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MY[0PEBpenN?		M1zZfWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG93[XKrYX6gZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iMUmuPVUh\|ryPLh?=	MkfNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
renal cancer cells	NE\yNY1EgXSxdH;4bYNqfHliYYPzZZk>		MX[0PEBpenN?		MmCwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdoVv[WxiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiVFfJJF0hOTlwOUWg{txONg>?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
ovarian cancer cells	MlPKR5l1d3SxeHnjbZR6KGG\|c3H5		MWe0PEBpenN?		NF;KU5pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBwfmG{aXHuJINidmOncjDj[YxteyCjZoTldkA1QCCqcoOsJHRIUSB;IEG5Mlk2KM7:TT6=	NFG1W4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0O\|c1QSd-MkS3OFc4PDl:L3G+
renal cancer cells	NGnzbnZEgXSxdH;4bYNqfHliYYPzZZk>		M1uxeVQ5KGi{cx?=		MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDy[Y5idCClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{NCCWR1mgQUAyQS57NTFOwG0v	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
ovarian cancer cells	Mn;sR5l1d3SxeHnjbZR6KGG\|c3H5		NXLzWohRPDhiaILz		Mof0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gc5ZiemmjbjDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSBzOT65OUDPxE1w	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
ovarian cancer cells	Mmn2R5l1d3SxeHnjbZR6KGG\|c3H5				MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDveoFzcWGwIHPhcoNmeiClZXzsd{whXEeLIE2gNVkvQTV{NjFOwG0v	NH7lVWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
renal cancer cells	MlHFR5l1d3SxeHnjbZR6KGG\|c3H5				M{PORWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJJmdmGuIHPhcoNmeiClZXzsd{whXEeLIE2gNVkvQTV{NjFOwG0v	NELXeWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
ovarian cancer cells	MWrBcpRqfHWvb4KgZZN{[Xl?		NIi5eGg1QCCqcoO=		Moi1RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5ib4\hdolidiClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygWGdKKD1iMUmuPVUzPiEQvF2u	NHTiXmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
renal cancer cells	MlPVRY51cXS3bX;yJIF{e2G7		MVu0PEBpenN?		MXLBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiC{ZX7hcEBk[W6lZYKgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiVFfJJF0hOTlwOUWyOkDPxE1w	NFTGWYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
renal tumor cells	MYTBcpRqfHWvb4KgZZN{[Xl?				M{PC[GFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JJJmdmGuIIT1cY9zKGOnbHzzMEBVT0liPTCxPU46PTJ4IN88UU4>	M1;KNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUW5NlA2Lz5zN{W1PVIxPTxxYU6=
ovarian tumor cells	MWrBcpRqfHWvb4KgZZN{[Xl?				M1TqOmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JI93[XKrYX6geJVud3JiY3XscJMtKFSJSTC9JFE6Njl3Mk[g{txONg>?	NYXuPIN5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
PC3	Ml3pR5l1d3SxeHnjbZR6KGG\|c3H5		NHvQNXo1QCCqcoO=		NH[4VmpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMkiuNVEh\|ryPLh?=	M1HjS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUe0PFE3Lz5{OUG3OFgyPjxxYU6=
neural precursor cells	M1LUTmZ2dmO2aX;uJIF{e2G7				NV7iNHhWUW6qaXLpeIlwdiCxZjDu[ZVzd3OyaHXy[UBxem:uaX\ldoF1cW:wIH;mJI1wfXOnIH7leZJidCCycnXjeZJ{d3JiY3XscJMh[nliTWTUJIF{e2G7	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzRzN{[zNUc,OTd2MUe2N\|E9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	MPM2 / Cyclin B1 / Cdc25c / p-Cdc2 / Cdc2 / Aurora B / p-H3 / p-PLK1; PubMed: 26156322 J Hematol Oncol MOLT-4 Cells were treated with vincristine (0.3, 1, and 3 nM) alone or co-treated with SAHA (500 nM) for 24 h. Then, total cell lysates were obtained to evaluate the G2/M phase regulatory protein expression and the tubulin acetylation. Data are expressed as mean values ± SD of at least three separate determinations. S SAHA, V vincristine	26156322
Growth inhibition assay	Cell viability ; PubMed: 26156322 J Hematol Oncol MOLT-4 cells were treated with various concentrations of vincristine for 24 and 48 h, respectively. Cell viability was measured by MTT assay.	26156322

In vivo

Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. ^[6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . ^[7]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: B16 melanoma cell
Concentrations: 10 nM
Incubation Time: 3 days
Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 10⁴ cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO₂ and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
(Only for Reference)

Animal Research:^[6]

- Collapse

Animal Models: Human rhabdomyosarcoma xenografts Rh12
Dosages: 3 mg/kg
Administration: A single i.p. administration
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL (108.33 mM)
	Water	60 mg/mL (65.0 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vincristine (NSC-67574) sulfate SDF

Molecular Weight	923.04
Formula	C₄₆H₅₈N₄O₁₄S
CAS No.	2068-78-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Leurocristine, Oncovin, 22-Oxovincaleukoblastine
Smiles	CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04448834	Not yet recruiting	Drug: Blinatumomab	B-cell Acute Lymphoblastic Leukemia	David Rizzieri MD\|Amgen\|Acrotech Biopharma LLC\|Duke University	April 1 2021	Phase 2
NCT03981510	Recruiting	Diagnostic Test: 3D-Transit	Constipation\|Childhood Acute Lymphoblastic Leukemia\|Neurofibromatosis 1\|Chronic Constipation With Overflow	University of Aarhus	June 13 2019	Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?
Answer:
According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Choose Your Country or Region

By Signaling Pathways

By product type

Vincristine (NSC-67574) sulfate